Pilla Scott J, Yeh Hsin-Chieh, Mitchell Christine M, Miller Edgar R, Oh Susan, White Karen, Durkin Nowella, Stein Ariella A, Charleston Jeanne B, Lu Mengyang, Hu Xiao, Wu Beiwen, Selvin Elizabeth, Fang Michael, Maruthur Nisa M, Juraschek Stephen P, Mueller Noel T, Wang Nae-Yuh, Appel Lawrence J
Division of General Internal Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland.
JAMA Intern Med. 2025 Jun 9. doi: 10.1001/jamainternmed.2025.1580.
People with type 2 diabetes and hypertension are at high risk for blood pressure-related cardiovascular events. Few trials have tested the blood pressure-lowering effects of dietary interventions other than weight loss in this population.
To determine the effects of dietary patterns and sodium reduction on blood pressure in adults with type 2 diabetes.
DESIGN, SETTING, AND PARTICIPANTS: Dietary Approaches to Stop Hypertension for Diabetes (DASH4D) was a randomized 4-period crossover feeding study conducted at a community-based study center from June 2021 to June 2024. It included adults with type 2 diabetes, a systolic blood pressure of 120 to 159 mm Hg, and a diastolic blood pressure of less than 100 mm Hg. The DASH4D diet is a Dietary Approaches to Stop Hypertension (DASH)-style diet optimized for people with type 2 diabetes (lower carbohydrates, higher unsaturated fats, and lower potassium than the original DASH diet). Participants were provided all of their food and ate no outside food. Weight was held constant. Data analysis was completed in November 2024.
Participants were randomized to a sequence of 4 diets, each for 5 weeks: (1) DASH4D diet with lower sodium, (2) DASH4D diet with higher sodium, (3) comparison (typical US) diet with lower sodium, and (4) comparison diet with higher sodium (reference).
The primary and secondary outcomes were end-of-period systolic and diastolic blood pressure, respectively. The primary dietary contrast compared the DASH4D lower sodium diet vs a comparison higher sodium diet.
Of 102 participants, 85 (83.3%) completed all diet periods. The mean (SD) age was 66 (8.8) years, 67 (66%) were women, 6 (6%) were self-reported Asian, 89 (87%) were Black, 2 (2%) were Hispanic, 6 (6%) were White, mean (SD) baseline blood pressure was 135 (9)/75 (9) mm Hg, and 67 (66%) used 2 or more antihypertensive medications. Compared with the comparison diet with higher sodium, the DASH4D diet with lower sodium reduced end-of-period systolic blood pressure by 4.6 mm Hg (95% CI, 7.2-2.0; P < .001) and diastolic blood pressure by 2.3 mm Hg (95% CI, 3.7-0.9). Most blood pressure reduction occurred during the first 3 weeks of each diet, and the effect of sodium reduction appeared stronger than the effect of the DASH4D diet. Adverse events were infrequent in each diet.
This randomized clinical trial found that, for adults with type 2 diabetes, most of whom were treated with multiple antihypertensive medications, the DASH4D diet combined with sodium reduction achieved a clinically relevant reduction in blood pressure, primarily from sodium reduction.
ClinicalTrials.gov Identifier: NCT04286555.
2型糖尿病合并高血压患者发生与血压相关的心血管事件的风险很高。在该人群中,除了减肥之外,很少有试验测试饮食干预对血压的降低作用。
确定饮食模式和减少钠摄入对2型糖尿病成年人血压的影响。
设计、地点和参与者:糖尿病患者高血压防治饮食研究(DASH4D)是一项于2021年6月至2024年6月在社区研究中心进行的随机4期交叉喂养研究。研究对象为2型糖尿病成年人,收缩压为120至159毫米汞柱,舒张压低于100毫米汞柱。DASH4D饮食是一种针对2型糖尿病患者优化的高血压防治饮食(DASH)式饮食(碳水化合物含量较低,不饱和脂肪含量较高,钾含量低于原始DASH饮食)。为参与者提供所有食物,他们不得食用外部食物。体重保持恒定。数据分析于2024年11月完成。
参与者被随机分配到4种饮食顺序,每种饮食持续5周:(1)低钠DASH4D饮食,(2)高钠DASH4D饮食,(3)低钠对照(典型美国)饮食,(4)高钠对照饮食(参考)。
主要结局和次要结局分别为期末收缩压和舒张压。主要饮食对比是比较低钠DASH4D饮食与高钠对照饮食。
102名参与者中,85名(83.3%)完成了所有饮食阶段。平均(标准差)年龄为66(8.8)岁,67名(66%)为女性,6名(6%)自我报告为亚洲人,89名(87%)为黑人,2名(2%)为西班牙裔,6名(6%)为白人,平均(标准差)基线血压为135(9)/75(9)毫米汞柱,67名(66%)使用2种或更多抗高血压药物。与高钠对照饮食相比,低钠DASH4D饮食使期末收缩压降低了4.6毫米汞柱(95%置信区间,7.2 - 2.0;P < 0.001),舒张压降低了2.3毫米汞柱(95%置信区间,3.7 - 0.9)。大多数血压降低发生在每种饮食的前3周,减少钠摄入的效果似乎比DASH4D饮食的效果更强。每种饮食中的不良事件都很少见。
这项随机临床试验发现,对于大多数接受多种抗高血压药物治疗的2型糖尿病成年人,DASH4D饮食与减少钠摄入相结合可实现临床上有意义的血压降低,主要是通过减少钠摄入实现的。
ClinicalTrials.gov标识符:NCT04286555。